ArticleSexual medicine2026
Understanding patient perspectives and preferences on sildenafil orodispersible formulation: a survey-based evaluation of men using erectile dysfunction medications.
Article in Sexual medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Erectile dysfunction (ED) is a common disease condition with major psychosocial and clinical consequences. Over 50% of men aged 40 years and above are estimated to experience some level of ED. Phosphodiesterase type 5 inhibitors (PDE5Is) remain the mainstay of ED treatment. Sildenafil citrate orodispersible film (ODF) is a novel formulation designed to improve convenience and patient satisfaction. This study explored real-world perspectives and patient preferences regarding the use of sildenafil citrate ODF. Methods: A cross-sectional, web-based survey was conducted in Italy (September-November 2024) in adult men using prescription ED medications. Data on demographics, lifestyle, clinical condition, treatment experiences, and patient perceptions about PDE5Is with a focus on sildenafil ODF were collected. Results: The survey included 276 men (mean age 47 years; 43.5% Viagra users, 25% Cialis users, 13.4% other branded ED medication users, and 18.1% generic ED medication users). Most were married (51%), employed (78%), and reported at least one comorbidity (75%), predominantly cardiovascular (53%). Film-coated tablets of PDE5 inhibitors were the most used formulation (72%), while 5% reported sildenafil ODF use.Awareness of sildenafil ODF was high, with valued attributes including water-free administration, portability, discretion, and faster perceived onset of action. Among overall ED medication users, 79% expressed willingness to adopt sildenafil ODF with 33% citing liking of the formulation and 28% citing perceived difference from already using medication. The main barrier to adoption was high cost compared to other ED medications, cited by 37% of the 21% participants who did not express willingness to adopt sildenafil ODF. Conclusion: Sildenafil ODF was widely perceived by patients as a discreet and practical alternative to conventional film-coated tablets, with high willingness for adoption. Aligning treatment choices with patient preferences may enhance adherence, satisfaction, and overall quality of life in ED management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.